NO310424B1 - cDNA som koder for IgE-reseptor <alfa>-underenhet eller fragment av denne, fremgangsmåte for fremstilling av löselig<alfa>-underenhet-polypeptid ved anvendelse av denne, samt vektorsom omfatter nevnte cDNA - Google Patents
cDNA som koder for IgE-reseptor <alfa>-underenhet eller fragment av denne, fremgangsmåte for fremstilling av löselig<alfa>-underenhet-polypeptid ved anvendelse av denne, samt vektorsom omfatter nevnte cDNA Download PDFInfo
- Publication number
- NO310424B1 NO310424B1 NO19902393A NO902393A NO310424B1 NO 310424 B1 NO310424 B1 NO 310424B1 NO 19902393 A NO19902393 A NO 19902393A NO 902393 A NO902393 A NO 902393A NO 310424 B1 NO310424 B1 NO 310424B1
- Authority
- NO
- Norway
- Prior art keywords
- subunit
- ige
- cdna
- alpha
- fragment
- Prior art date
Links
- 239000002299 complementary DNA Substances 0.000 title claims abstract description 36
- 239000012634 fragment Substances 0.000 title claims abstract description 24
- 239000013598 vector Substances 0.000 title claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 15
- 229920001184 polypeptide Polymers 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 102000009438 IgE Receptors Human genes 0.000 title description 30
- 108010073816 IgE Receptors Proteins 0.000 title description 30
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 208000026935 allergic disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- -1 acetic Chemical class 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004395 cytoplasmic granule Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/127,214 US4962035A (en) | 1987-12-01 | 1987-12-01 | DNA encoding IgE receptor alpha-subunit or fragment thereof |
| PCT/US1988/004255 WO1989005352A1 (en) | 1987-12-01 | 1988-11-29 | DNA ENCODING IgE RECEPTOR alpha-SUBUNIT OR FRAGMENT THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO902393L NO902393L (no) | 1990-05-30 |
| NO902393D0 NO902393D0 (no) | 1990-05-30 |
| NO310424B1 true NO310424B1 (no) | 2001-07-02 |
Family
ID=22428905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19902393A NO310424B1 (no) | 1987-12-01 | 1990-05-30 | cDNA som koder for IgE-reseptor <alfa>-underenhet eller fragment av denne, fremgangsmåte for fremstilling av löselig<alfa>-underenhet-polypeptid ved anvendelse av denne, samt vektorsom omfatter nevnte cDNA |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US4962035A (ko) |
| EP (1) | EP0394302B1 (ko) |
| JP (1) | JP3117206B2 (ko) |
| KR (1) | KR970009936B1 (ko) |
| AT (1) | ATE177148T1 (ko) |
| AU (1) | AU625434B2 (ko) |
| CA (1) | CA1341538C (ko) |
| DE (1) | DE3856309T2 (ko) |
| DK (2) | DK175974B1 (ko) |
| NO (1) | NO310424B1 (ko) |
| WO (1) | WO1989005352A1 (ko) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451669A (en) * | 1986-05-29 | 1995-09-19 | The University Of Melbourne | DNA encoding for an Fc receptor for immunoglobulin |
| US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US5639660A (en) | 1988-02-24 | 1997-06-17 | Hoffmann-La Roche Inc. | Polypeptide and DNA sequence corresponding to the human receptor with high affinity for IgE |
| CA2059842A1 (en) * | 1991-02-11 | 1992-08-12 | Richard A. Chizzonite | Ige-receptor-antibodies |
| US5516651A (en) * | 1991-11-15 | 1996-05-14 | The General Hospital Corporation | Nucleic acids encoding calcitonin receptor and uses thereof |
| US5770396A (en) | 1992-04-16 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E |
| EP0657534A4 (en) * | 1992-08-04 | 1997-06-04 | Green Cross Corp | ANTIALLERGIC AGENT. |
| US5874404A (en) * | 1992-08-04 | 1999-02-23 | Chisei Ra | Immunoglobulin E receptor α-chain inhibits IgE production and secondary allergic responses |
| CA2176811C (en) * | 1993-12-10 | 2008-01-29 | David Tai Wai Fei | Methods for diagnosis of allergy and screening of anti-allergy therapeutics |
| DE69501817T2 (de) * | 1994-01-18 | 1998-09-10 | Genentech Inc | Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US20040197326A1 (en) * | 1995-07-27 | 2004-10-07 | Genentech, Inc. | Method for treatment of allergic asthma |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9526599D0 (en) | 1995-12-28 | 1996-02-28 | Sandoz Ltd | Elisa test system |
| MY120425A (en) * | 1996-07-26 | 2005-10-31 | Novartis Ag | Fusion polypeptides |
| US6423512B1 (en) | 1996-07-26 | 2002-07-23 | Novartis Ag | Fusion polypeptides |
| US6391569B1 (en) | 1996-09-18 | 2002-05-21 | Heska Corporation | Method to detect Dirofilaria immitis infection |
| US5945294A (en) * | 1996-11-26 | 1999-08-31 | Heska Corporation | Method to detect IgE |
| AU769954B2 (en) * | 1996-11-26 | 2004-02-12 | Heska Corporation | Method to detect IgE |
| US5958880A (en) * | 1996-12-19 | 1999-09-28 | Heska Corporation | Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof |
| US6060326A (en) * | 1997-04-07 | 2000-05-09 | Heska Corporation | Method to detect canine IgE and kit therefor |
| US6057127A (en) * | 1998-01-29 | 2000-05-02 | Heska Corporation | Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof |
| JP2002533060A (ja) * | 1998-11-05 | 2002-10-08 | ヘスカ コーポレイション | 結晶化型のＦｃイプシロンレセプタアルファ鎖、その３−Ｄモデル、及びそれらの利用法 |
| US6889145B1 (en) * | 2000-03-15 | 2005-05-03 | Northwestern University | Three-dimensional model of a Fc region of an IgE antibody and uses thereof |
| CA2403739A1 (en) * | 2000-03-15 | 2001-09-20 | Heska Corporation | Three-dimensional model of a complex between a fc epsilon receptor alpha chain and a fc region of an ige antibody and uses thereof |
| US20030022250A1 (en) * | 2001-05-29 | 2003-01-30 | Dreskin Stephen C. | Functional IgE test methods and compositions |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
| CN110716054A (zh) * | 2019-09-11 | 2020-01-21 | 天津医科大学 | 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6385886A (en) * | 1986-10-10 | 1988-04-14 | Medical Biology Institute | Production of ige-binding protein by recombinant methods |
-
1987
- 1987-12-01 US US07/127,214 patent/US4962035A/en not_active Expired - Fee Related
-
1988
- 1988-11-29 WO PCT/US1988/004255 patent/WO1989005352A1/en active IP Right Grant
- 1988-11-29 AU AU26105/88A patent/AU625434B2/en not_active Expired
- 1988-11-29 JP JP01500240A patent/JP3117206B2/ja not_active Expired - Lifetime
- 1988-11-29 AT AT89900039T patent/ATE177148T1/de not_active IP Right Cessation
- 1988-11-29 EP EP89900039A patent/EP0394302B1/en not_active Expired - Lifetime
- 1988-11-29 KR KR1019890701432A patent/KR970009936B1/ko not_active IP Right Cessation
- 1988-11-29 DE DE3856309T patent/DE3856309T2/de not_active Expired - Lifetime
- 1988-11-30 CA CA000584536A patent/CA1341538C/en active Active
-
1990
- 1990-05-30 NO NO19902393A patent/NO310424B1/no unknown
- 1990-05-31 DK DK199001347A patent/DK175974B1/da not_active IP Right Cessation
-
1993
- 1993-09-29 US US08/128,321 patent/US7202333B1/en not_active Expired - Lifetime
-
2005
- 2005-05-11 DK DK200500682A patent/DK176181B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR970009936B1 (ko) | 1997-06-19 |
| AU625434B2 (en) | 1992-07-09 |
| NO902393L (no) | 1990-05-30 |
| JPH03502878A (ja) | 1991-07-04 |
| NO902393D0 (no) | 1990-05-30 |
| JP3117206B2 (ja) | 2000-12-11 |
| DK176181B1 (da) | 2006-12-11 |
| ATE177148T1 (de) | 1999-03-15 |
| DK134790A (da) | 1990-07-25 |
| DK134790D0 (da) | 1990-05-31 |
| US7202333B1 (en) | 2007-04-10 |
| EP0394302B1 (en) | 1999-03-03 |
| EP0394302A1 (en) | 1990-10-31 |
| EP0394302A4 (en) | 1991-09-11 |
| DK200500682A (da) | 2005-05-11 |
| DE3856309D1 (de) | 1999-04-08 |
| CA1341538C (en) | 2007-08-28 |
| WO1989005352A1 (en) | 1989-06-15 |
| US4962035A (en) | 1990-10-09 |
| DE3856309T2 (de) | 1999-07-15 |
| KR900700600A (ko) | 1990-08-16 |
| AU2610588A (en) | 1989-07-05 |
| DK175974B1 (da) | 2005-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO310424B1 (no) | cDNA som koder for IgE-reseptor <alfa>-underenhet eller fragment av denne, fremgangsmåte for fremstilling av löselig<alfa>-underenhet-polypeptid ved anvendelse av denne, samt vektorsom omfatter nevnte cDNA | |
| EP0413908B2 (en) | Soluble extracellular fragment of the human IFN-beta 2/IL-6 receptor, its preparation and pharmaceutical compositions containing it | |
| RU2197525C2 (ru) | Полинуклеотидная последовательность, кодирующая протокадгерин pc3, pc4, pc5 (варианты), полипептид протокадгерина pc3, pc4, pc5 (варианты) | |
| JPH02501113A (ja) | リンパ球機能関連抗原―３（ｌｆａ―３）を製造するためのｄｎａ配列、組換ｄｎａ分子及び方法 | |
| EP0904369A1 (en) | Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases | |
| AU8767698A (en) | Novel orphan receptor | |
| EP0341290B1 (en) | Immunoglobulin e competitor | |
| NO316917B1 (no) | Fremgangsmate til fremstilling av et farmasoytisk preparat inneholdende en interleukin-1-inhibitor | |
| JP2002537796A (ja) | ヒトグリコシル化酵素 | |
| JP2718827B2 (ja) | 分泌Ｍａｃ−２結合糖タンパク質 | |
| CA2263827A1 (en) | Fibroblast growth factor homologous factors (fhfs) and methods of use | |
| JPH11507513A (ja) | Ｃ５ａ様７膜貫通受容体 | |
| US5208144A (en) | Method for detection of human dna containing the gene encoding low density lipoprotein receptor | |
| CA2046925A1 (en) | Pregnancy specific proteins applications | |
| JPH10512154A (ja) | 膵臓で発現する新規なケモカイン | |
| US20030004101A1 (en) | Peptides derived from the human amyloid precursor protein | |
| EP0358977A1 (en) | Cloned nephritis antigen | |
| AU645965C (en) | Pregnancy specific proteins applications | |
| CN118027168A (zh) | 基于真核表达的msl重组植物蛋白的制备方法及用途 | |
| US5830754A (en) | Recombinant DNA-produced T11 and fragments thereof | |
| JPH11506912A (ja) | 新規なヒトプリンｐ▲下２ｕ▼受容体 | |
| CA2386815A1 (en) | Immunoregulatory compositions | |
| IL90488A (en) | Ifn-beta2/il-6 receptor its preparation and pharmaceutical compositions containing it | |
| JPH11514968A (ja) | 筋無力症の処置のためのヌクレオチドおよびペプチド配列 |